|
| Status |
Public on Jan 01, 2012 |
| Title |
PC3-docetaxel resistant-rep3 |
| Sample type |
RNA |
| |
|
| Source name |
PC3 cell line resistant to docetaxel
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: PC3
disease state: metastatic prostate cancer
treatment: converted to docetaxel-resistant cells
|
| Treatment protocol |
The human prostate carcinoma cell lines DU-145 and PC-3 (obtained from American Tissue Culture Collection) were converted to docetaxel-resistant cells by exposing them to an initial dose of 5 nM docetaxel and culturing surviving cells during 1 yr and 6 mo, respectively, with increasing doses in an intermittent regimen. Docetaxel (Sigma) was dissolved in DMSO (10mM).
|
| Growth protocol |
DU-145 and DU-145R cell lines were cultured in RPMI 1640 medium (Invitrogen), and PC-3 and PC-3R in F-12K nutrient mixture medium (Invitrogen), both supplemented with 10% fetal bovine serum.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Trizol extraction of total RNA was performed according to the manufacturer's instructions.
|
| Label |
biotin
|
| Label protocol |
Biotinylated cRNA were prepared according to the Affymetrix IVT Labeling kit from 2ug total RNA.
|
| |
|
| Hybridization protocol |
GeneChip Hybridization wash and stain kit
|
| Scan protocol |
GeneChip 3000 Scanner 3000 7G system; software: GeneChip Command Console (AGCC 1.1)
|
| Data processing |
Raw expression measures were summarized after background correction and normalization steps using the rma methodology in the affy package from the Bioconductor project.
|
| |
|
| Submission date |
Nov 03, 2011 |
| Last update date |
Mar 12, 2020 |
| Contact name |
Mercedes Marín-Aguilera |
| E-mail(s) |
[email protected]
|
| Organization name |
Fundació Clínic per a la Recerca Biomèdica
|
| Street address |
Villarroel 170
|
| City |
Barcelona |
| ZIP/Postal code |
08036 |
| Country |
Spain |
| |
|
| Platform ID |
GPL570 |
| Series (1) |
| GSE33455 |
Expression data from docetaxel-resistant prostate cancer cell lines |
|
